Investor Ideas, Trading Ideas and Stocks to Watch : #AIEye Episode 431: NVIDIA (NasdaqGS: $NVDA) to Acquire Arm Limited from SoftBank Group (OTC: $SFTBY), BrainChip (ASX:BRN) Exhibiting Akida at 2020 Embedded Vision Summit Virtual Conference

Monday, September 14, 2020

#AIEye Episode 431: NVIDIA (NasdaqGS: $NVDA) to Acquire Arm Limited from SoftBank Group (OTC: $SFTBY), BrainChip (ASX:BRN) Exhibiting Akida at 2020 Embedded Vision Summit Virtual Conference

#AIEye Episode 431: NVIDIA (NasdaqGS: $NVDA) to Acquire Arm Limited from SoftBank Group (OTC: $SFTBY), BrainChip (ASX:BRN) Exhibiting Akida at 2020 Embedded Vision Summit Virtual Conference

#AI in Drug Discovery Market to Register 28.8% CAGR from 2020-2027

Point Roberts WA, Vancouver BC – September 14, 2020 – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye- watching stock news, deal tracker and advancements in artificial intelligence.

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2020/091420-AI-Eye.mp3

Read this in full at https://www.investorideas.com/news/2020/artificial-intelligence/09141AIEye-NVDA-SoftBank-BrainChip.asp

Hear the Ai Eye on Spotify

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

Stocks discussed: (NasdaqGS:NVDA) (OTC:SFTBY) (ASX:BRN)

NVIDIA Corporation (NasdaqGS:NVDA) has announced a definitive agreement with SoftBank Group (OTC:SFTBY) through which NVIDIA will acquire Arm Limited from SoftBank Group and the SoftBank Vision Fund for $40 billion. According to the press release, this acquisition couples “NVIDIA’s leading AI computing platform with Arm’s vast ecosystem to create the premier computing company for the age of artificial intelligence, accelerating innovation while expanding into large, high-growth markets.” Jensen Huang, founder and CEO of NVIDIA, commented:

“AI is the most powerful technology force of our time and has launched a new wave of computing. In the years ahead, trillions of computers running AI will create a new internet-of-things that is thousands of times larger than today’s internet-of-people. Our combination will create a company fabulously positioned for the age of AI.

Simon Segars and his team at Arm have built an extraordinary company that is contributing to nearly every technology market in the world. Uniting NVIDIA’s AI computing capabilities with the vast ecosystem of Arm’s CPU, we can advance computing from the cloud, smartphones, PCs, self-driving cars and robotics, to edge IoT, and expand AI computing to every corner of the globe.”

BrainChip Holdings Ltd (ASX:BRN) is participating at the 2020 Embedded Vision Summit Virtual Conference starting tomorrow, September 15, and running to September 25. There, the company will be exhibiting Akida, its AI-powered, ultra-low power, event domain neural processor. Louis DiNardo, BrainChip’s CEO, said:

"While we would love the opportunity to showcase our Akida solution in person to attendees of the Embedded Vision Summit, presenting from our virtual booth actually enables us to demonstrate Akida’s abilities to a potentially larger audience joining from home. We’re eager to show attendees how Akida helps organizations create ultra-low power chips with our licensed intellectual property and high- performance power efficient systems with our integrated circuit. Akida provides the ability to incrementally learn on-chip without the need to retrain in the Cloud. This ability makes us uniquely positioned to help deliver the next generation of AI at the Edge. It’s an exhibit you definitely don’t want to miss."

AI in Drug Discovery Market to Register 28.8% CAGR from 2020-2027

A report from Grand View Research finds that the global AI in Drug Discovery market, which was valued at $473.4 million in 2019, will exhibit a compound annual growth rate (CAGR) of 28.8 percent in the forecast period 2020-2027. An excerpt from the report summary reads:

Another key factor promoting the adoption of artificial intelligence in the drug discovery space is the monumental data generated by the molecule screening processes and the preclinical studies. The large data makes it a difficult process for the scientist to review all the scientific literature. In such cases, artificial intelligence can help boost up the screening process and reduce the time required for studying and identify drug molecule interactions and histology data.

Sam Mowers, Investorideas.com

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on Investorideas.com visit here or become an Investor Ideas member

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .

The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com